Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trialVincent C. Marconi, E. Wesley Ely, Athimalaipet V Ramanan et al.|medRxiv|2021Cited by 36
Genome-Wide Mapping and Interrogation of the Nmp4 Antianabolic Bone AxisPaul Childress, Joseph P. Bidwell, Keith R. Stayrook et al.|Molecular Endocrinology|2015Cited by 16
Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidismVenkatesh Krishnan, Henry U. Bryant, Yanfei Li et al.|British Journal of Pharmacology|2017Cited by 16
Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERGJustin M. Roberts, Nancy L. Weigel, David R. Rowley et al.|Oncotarget|2017Cited by 2